Get Ready For The Bell: Low Float (HILS) Has 4 Potential Breakout Catalysts (Past Champ)

Ready to get back to it? You should be. Here's why. Get Ready For The Bell: Low Float (HILS) Has 4 Potential Breakout Catalysts (Past Champ) July 20th Dear Reader, Ready to get back to it? You should be. Here's why. We've got a past champ back on alert. When I brought this profile to your attention previously, it turned into a short term breakout star. Running approximately 100+% in the span of days, this Nasdaq profile could not be squashed. Now, based on several new potential catalysts, it needs to be back on radar. First off, volatility will need to be on high watch again as this profile has a float of fewer than 10Mn shares according to Yahoo Finance. Going through significant changes recently, this company has announced a game-changing collaboration that could put them on the map as a cancer-killing juggernaut in the years to come. With this collaboration, the company has also announced their pipeline has changed focus. This new pipeline's potential to create value in the short-term could really start gaining traction on Wall Street before the year's out. But before that happens, this is your chance to once again get them on your radar. Drop everything right now and pull up: Hillstream BioPharma, Inc. (HILS) Hillstream BioPharma, Inc. is a biotechnology company developing a focused portfolio of therapeutic candidates targeting drug resistant and devastating cancers. The Company’s emerging immuno-oncology pipeline is led by HSB-3215, a novel anti-HER2 monoclonal antibody targeting unique epitopes with a novel mechanism of action. And based on these several potential catalysts, HILS needs immediate attention. Check them out: No. 1 - A Low Float Could Lead To Explosive Volatility (Again!) No. 2 - A Pipeline Reprioritization Aims To Provide Near-Term Value Creation No. 3 - Exclusive Agreement With Leading Institute Will Help Build Antibody Platform To Advance Pipeline No. 4 - Experienced New Hire To Board Of Directors Will Help Further Ongoing Development Programs But more on those in a second... Hillstream BioPharma's Mission “To improve and transform the lives of patients with drug resistant and devastating rare cancers, through our cutting-edge drug development platform.” Lead Program: HSB-3215 (HER2/HER3 Bispecific Antibody) Background - HER2/neu is a tumor-specific oncogene that has been extensively studied - HER3 promotes metastasis & drug resistance by interacting with HER2 (and other receptors) drastically - HER2 and HER3 are overexpressed in multiple solid tumors including breast, GI, ovarian, and bladder, colon and other sites associated with a highly aggressive infiltrating type of tumor prone to metastatic spreading Opp. - HER3 has poor to no oncogenic activity alone - HER3 heterodimerizes preferentially with HER2 and/or EGFR, which dramatically enhance transphosphorylation and the consequent activation of mitogenic downstream pathways Target Validation - Validated targets – HER2 extensively studied and multiple stand-alone & antibody-drug conjugates approved – HER3 monoclonal and bispecific antibodies in various forms being studied in clinical trials HSB-3215 (HER2 x HER3 bispecific antibody) - Bispecific mAb selective for both HER2 & HER3 - Platform molecule with follow-on antibody-drug conjugates - IND Filing: planned for late 2024 Solid Tumor Pipeline: Validated Targets & Unmet Needs HSB-3215: anti-HER2/HER3 bispecific Ab The ErbB family of cell surface proteins are some of the most well-known and validated oncology drug targets including ErbB2 or HER2 (human epidermal growth factor receptor) and Erb3 or HER3. The family of antibodies and biologics against HER2 starting with HERCEPTIN® (trastuzumab) approved in 1998 for breast cancer, one of the first few anti-cancer antibodies, as well as PERJETA®, KADCYLA® and PHESGO® totaled $8.4Bn in 2022 sales for Roche/Genentech. Antibodies against HER2 and HER3 bind to different domains of the extracellular portion of the proteins or epitopes with trastuzumab binding domain IV of HER2 primarily. HER2 is also one of the most utilized targeting antigens for antibody drug conjugates to treat HER2 positive cancers with two approved antibodies, Roche/Genentech’s PERJETA® and Daiichi Sankyo/AstraZeneca’s ENHERTU®. The Applied Biomedical Science Institute has developed technology to target unique functional epitopes of the cancer targets HER2 and HER3. Monoclonal antibodies being developed at ABSI are unique from the currently approved anti-HER2 antibodies. ABSI has granted under an exclusive option agreement to Hillstream, certain of its proprietary technology which if converted to an exclusive license agreement, will allow Hillstream to develop HER2 and HER3 antibodies, including multi-specific and Quatramer- based therapeutics incorporating portions of the antibodies. HSB-0059: Bispecific ADC Antibody Drug Conjugates (ADCs) are a class of newly emerging therapeutics which may serve as “magic bullets” to treat certain cancers. They consist of a 1) a cancer killing chemotherapeutic payload, 2) an antibody-targeting a cancer cell and 3) a linker connecting the antibody to the payload. The problem with some ADCs targeting HER2 and/or HER3 essentially target the same epitopes as trastuzumab based domains. Our solution based on data an HSB-3215 (HER2/HER3) mAb backbone with HSB-0059 targets novel epitopes on HER2 while blocking natural ligands to HER3 and/or preventing heterodimers. ADCs can also have a potential “bystander effect” of its’ toxin payload. We intend to design ADCs whereby the toxin delivered to surrounding non-antigenic cancer tissue can be killed and maximize antitumor potential for this novel compound. HSB-1940: Anti-PD-1 (Undruggable Epitopes) Picobodies are antibody “knob” domains comprised of cysteine-rich ultralong complementary determining region (CDR) H3 sequences of 30-40 amino acids, which have the potential to access challenging epitopes better than full size antibodies can. By combining Quatramers with their long half-life coated with a PD-1 Picobody™ to create HSB-1940, we intend to efficiently target novel epitopes with greater binding affinity than approved biologics. Antibodies derived from mouse or human sources use the surface formed by complementarity determining regions (CDRs) on the variable regions of the heavy chain/light chain heterodimer, which typically forms a relatively flat binding surface. Alternative species, particularly camelids and bovines, provide a paradigm for antigen recognition through novel domains which form the antigen binding site. However, for camelids, heavy chain antibodies bind antigen with only a single heavy chain variable region, in the absence of light chains. Meanwhile, in bovines, ultralong CDR-H3 regions form an independently folding mini-domain, which protrudes far out from the surface of the antibody and forms a “stalk and knob” structure which is diverse in both its sequence and disulfide patterns. The “knob” (Picobody) component can be expressed as an independent antigen binding domain. At ~4-6 kDa, these are three times smaller than a camelid “nanobody”, and are the smallest known antibody fragment. These atypical antigen binding sites of bovines potentially provide the ability to interact with different antigenic determinants, particularly recessed or concave surfaces, compared to traditional antibodies. Sources: [Company Website.]( [Company Presentation.]( ----- As mentioned above, HILS needs your full focus now based on several potential catalysts. Check them out: No. 1 HILS Potential Catalyst - A Low Float Could Lead To Explosive Volatility (Again!) According to the [Yahoo Finance]( website, HILS has a low float. The website reports this profile to have roughly 9.78Mn shares in its float. Why is that important? It's important on one crucial level. Volatility. Could more positive 2023 company news help provide a near term spark? Remember: This was an explosive breakout idea previously that ran approximately 100+% in the short term after I brought it to your attention previously. A low float may have created the potential for such a volatile move... ----- No. 2 HILS Potential Catalyst - A Pipeline Reprioritization Aims To Provide Near-Term Value Creation Hillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2/HER3 Solid Tumors via Bispecific and ADC Antibodies and Biologics Lead bispecific antibody, HSB-3215 designed to target novel conformational epitopes on high value validated targets, HER2 and HER3 Focus on optimizing ADCs to generate a more potent Bystander Effect and proprietary novel bovine-derived biologic platform, PicoKnobTM, targeting undruggable epitopes on PD-1 and TROP2 Experienced biopharmaceutical executive joins as Chief Operating Officer to spearhead execution of ADC and biologic strategy BRIDGEWATER, N.J., July 10, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma (Nasdaq: HILS) a biotechnology company developing innovative therapeutic candidates targeting drug resistant and devastating cancers that can make a difference in patients’ lives, today announced a strategic reprioritization of its pipeline and provided a corporate update. The strategic assessment took into account, the pipeline’s near-term value creation opp. and other factors. Hillstream will focus its pipeline on advancing novel oncology assets with the greatest potential and strong competitive profiles to address unmet needs across multiple solid tumors, such as bispecific antibodies and ADCs targeting novel conformational epitopes on high value validated targets, HER2 and HER3, with a more potent Bystander Effect. ... Hillstream’s lead asset, HSB-3215 is designed as a bispecific humanized immunoglobulin containing two arms targeting the extracellular domains of HER2 and HER3. HSB-3215 binds to both overlapping and different epitopes on HER2 when compared to trastuzumab, the first approved antibody against HER2, while adhering to novel epitopes on HER3, thus creating novel conformational epitopes. The Company intends to develop this novel BsAb and file an IND application with the US FDA late next year. By exploiting the “Bystander Effect”, a key aspect of ADCs which has been recently highlighted by the improved clinical efficacy of Daiichi Sankyo/AstraZeneca’s ENHERTU® (trastuzumab deruxtecan), the Company plans to optimize its BsAb pipeline with BiSpecific ADCs, i.e. BiSpecific antibodies conjugated with novel toxin payloads which are optimized to generate a more powerful Bystander Effect. ADCs are comprised of a targeting antibody chemically conjugated via a proprietary linker to a powerful, cancer-killing compound/toxin (payload). With a BsAb backbone utilizing HSB-3215, the Company intends to develop novel ADCs, targeting HER2/HER3 and better direct a payload to cancer cells overexpressing these receptors, while healthy cells don’t take up the unwanted compound. Hillstream also intends to further enhance its previously announced collaborations with Applied Biomedical Science Institute (ABSI) and Minotaur to develop novel bovine-derived biologics in multiple formats against highly validated targets, including PD-1, HER2 and TROP-2, referred to as PicoKnobsTM. An update regarding these collaborations will be announced during an R&D Day in the third quarter. “Our recently announced collaborations with ABSI are transforming Hillstream into a focused and targeted cancer biologics company,” said Randy Milby, Chairman and CEO of Hillstream. “With the HER2 and HER3 platform, we are building a diverse foundation of targeted biologics which can be utilized for our current portfolio as well for future in-licensed assets. We are confident that our focused approach and experienced management team best positions us for success.” The Company also announced the appointment of Sireesh Appajosyula, Pharm. D .as as Chief Operating Officer (COO). Sireesh brings over 20 years of experience in creating and advising biotechnology companies such as 9 Meters Biopharma Inc. through targeted transactions thus creating a pipeline as well as accessing the public capital markets. He was responsible for corporate development including portfolio strategy, in-licensing transactions and alliances for 9 Meters’s core assets as well as monetization of non-core assets. Previously, he spent eight years at Salix Pharmaceuticals, Inc. in various roles including medical & clinical affairs, product commercialization and business development culminating in Salix’s acquisition for $16Bn by Bausch Health. Prior to Salix, Sireesh held increasing roles and responsibilities at Amgen, Chiesi (Critical Therapeutics) and Sanofi S.A. (Aventis). Sireesh holds a Doctor of Pharmacy degree from the Ernest Mario College of Pharmacy at Rutgers University in New Jersey. “I am thrilled to join Hillstream and look forward to working alongside the team as we further our development programs. I believe the Company’s precision oncology strategy with the current HER2/HER3 antibody programs and pipeline have the potential to bring much needed treatments to cancer patients,” said Dr. Appajosyula. [Read the full article here.]( ----- No. 3 HILS Potential Catalyst - Exclusive Agreement With Leading Institute Will Help Build Antibody Platform To Advance Pipeline Hillstream BioPharma Licenses Technology to Develop Proprietary HER2 and HER3 Antibody Drug Conjugates against Drug-Resistant Breast, Lung, Gastric, and Ovarian Cancers Anti-HER2 and Anti-HER3 monoclonal antibodies designed to have a high drug-to-antibody ratio intended enhance the bystander killing effect and be effective against a number of epithelial tumors Antibody CDRs against HER2 and HER3 Conformational Domain Bridging Epitopes can be used in multiple formats including bi- and tri-specific antibodies, antibody drug conjugates (ADCs), CAR-T and CAR-NKs BRIDGEWATER, N.J., July 06, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers using immuno-oncology targeted novel biologics, today announced the signing of an exclusive agreement with Applied Biomedical Science Institute (ABSI) to license technology for human antibodies targeting novel HER2 and HER3 Conformational Epitopes. The goal is to develop proprietary multi-format biologics, including bi-specific antibodies, and antibody drug conjugates (ADCs). The HER2/HER3 binding ADC is targeted to have a high drug-to-antibody ratio which should increase the anti-tumoral efficacy with an enhanced bystander killing effect. Hillstream intends to combat drug resistant cancers such as HER2-positive metastatic breast cancer, gastric cancer, lung cancer and ovarian cancer. The ErbB family of cell surface proteins, including ErbB2 or HER2 (human epidermal growth factor receptor) and Erb3 or HER3, are some of the most well-known and validated oncology drug targets. Antibodies and biologics against HER2 starting with HERCEPTIN® (trastuzumab) approved in 1998 for breast cancer, and PERJETA®, KADCYLA® and PHESGO® generated $8.4Bn in 2022 sales for Roche/Genentech. These antibodies bind to domains II or IV of the extracellular portion of the HER2. HER2 is also one of the most validated antigens for antibody drug conjugates (ADCs) to treat HER2 positive cancers with two approved antibodies, Roche/Genentech’s KADCYLA® and Daiichi Sankyo/AstraZeneca’s ENHERTU®. The Applied Biomedical Science Institute has developed technology to target novel functional epitopes of the cancer targets HER2 and HER3. The monoclonal antibodies being developed at ABSI are distinct from the currently approved anti-HER2 antibodies. ABSI has granted Hillstream an exclusive license agreement, and Hillstream will have the opportunity to develop HER2 and HER3 antibodies, including multi-specific, ADC, and Quatramer-based therapeutics utilizing portions of these antibodies. “We look forward to this opp. to work with Dr. Smider and the Applied Biomedical Science Institute,” said Randy Milby, CEO of Hillstream. “This agreement allows us to build our antibody platform to advance our immune-oncology biologic pipeline with HER2 and HER3 with bi-specifics and ADC agents targeting highly aggressive drug-resistant metastatic tumors, which represents a major unmet need for patients.” [Read the full article here.]( ----- No. 4 HILS Potential Catalyst - Experienced New Hire To Board Of Directors Will Help Further Ongoing Development Programs Hillstream BioPharma Strengthens its Board of Directors with Appointment of Kelly Anderson BRIDGEWATER, N.J., May 15, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers using ferroptosis, an emerging new anti-cancer mechanism resulting in iron-mediated cell death, and immuno-oncology targeted novel biologics, today announced the appointment of Kelly Anderson to its Board of Directors and committees, effective as of May 9, 2023. Mrs. Anderson brings over 25 years of experience in public company fi-nan-ce, accounting and corporate governance across a variety of industries and will be instrumental in guiding Hillstream with its organizational management, business development and research and development initiatives. “Kelly has served as a CFO and brings expertise in partnering negotiations and business development,” said Randy Milby, Chairman and CEO of Hillstream. “We believe her proven cross-industry experience and track record of building sustainable long-term value will further bolster our Board’s depth of expertise and diversity of thought especially as we further develop our immuno-oncology targeted biologics portfolio led by anti-HER2 and anti-HER3 monoclonal antibodies. As such, it is a top priority for us to have the right team in place to guide us through the execution of our goals so that we can expand our efforts to develop and commercialize on our drug candidates.” “I am excited to be joining the Board of Hillstream BioPharma and look forward to working alongside the team as we further our ongoing development programs. I believe the Company’s precision medicine immuno-oncology strategy with the current HER2/HER3 antibody developments, has the potential to bring much needed treatments to cancer patients,” said Mrs. Anderson. Kelly Anderson currently serves as Chief Executive Officer of CXO Executive Solutions, a specialized executive talent solutions company. From 2015 through 2020, she served as a partner in C Suite Fin-an-cial Partners, a fi-nan-cial consulting firm serving private, private equity, entrepreneurial, family office and government-owned firms across the entertainment, aerospace/defense, Software-as-a-Service and manufacturing industries. Mrs. Anderson previously served in senior fi-nan-cial executive posts at companies including Mavenlink (now known as Kantata), Ener-Core, Fisker Automotive, T3 Motion and The First American Corporation. In addition, Mrs. Anderson currently serves as on the board of AgEagle Aerial Systems Inc., Tomi Environmental Solutions and Concierge Technologies and was previously a member of the board of directors of Marygold Companies, Guardion Health Sciences and Psychic Friends Network. She is a Certified Public Accountant in California and received her B.A. in business administration with an accounting concentration from California State University, Fullerton. [Read the full article here.]( ----- HILS Recap - The Top Potential Breakout Catalysts To Know Right Now No. 1 - A Low Float Could Lead To Explosive Volatility (Again!) No. 2 - A Pipeline Reprioritization Aims To Provide Near-Term Value Creation No. 3 - Exclusive Agreement With Leading Institute Will Help Build Antibody Platform To Advance Pipeline No. 4 - Experienced New Hire To Board Of Directors Will Help Further Ongoing Development Programs ----- Coverage is reinitiated on HILS. When you have a chance, do this: Get HILS on your radar now. Sincerely, FierceAnalyst | Jaks Swift Editorial Writer (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) FierceInvestor (FierceInvestor . com) is owned by SWN Media LLC, a limited liability company. Ownership of FI has now moved to a single individual. Disclosure: I am not a lic-ensed fina-ncial adviser. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. Fierce full disclosure is to be read and fully understood before using Fierce's website, or joining Fierce's email or text list. By viewing Fierce's website and/or reading Fierce's email or text newsletter you are agreeing to -> [( An owner of SWN Media LLC owns and operates smallcapfirm . com (“SCF”), owns and operates stockwirenews . com (“SWN”), and owns and operates stockstreetwire . com ("SSW"). From time to time, SWN, SCF, FI, and/or SSW will publicly disseminate information about a company via website, email, SMS and other points of media. Pursuant to an agreement between SWN Media LLC and Legends Media LLC, FierceInvestor (FI) has been hired for a period beginning on 2/1/23 and ending on 2/2/23 to publicly disseminate information about (HILS) via Website, Email and SMS. SWN Media LLC was paid twenty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (HILS). Pursuant to an agreement between SWN Media LLC and TD Media LLC, FierceInvestor (FI) has been hired for a period beginning on 7/18/23 and ending on 7/19/23 to publicly disseminate information about (HILS) via Website, Email and SMS. SWN Media LLC was paid twenty thousand USD via bank wire transfer. We own zero shares of (HILS). To date we've now been compensated a total of forty-seven thousand five hundred USD via bank wire transfer to disseminate information about (HILS). A member of SWN Media LLC is also a member of TD Media LLC. Pursuant to an agreement between TD Media LLC and Sica Media LLC, TD Media LLC has been hired for a period beginning on 07/18/2023 and ending on 07/19/2023 to publicly disseminate information about (HILS:US) via digital communications. We have been paid an additional sixty seven thousand five hundred dollars USD. To date we have been paid one hundred ninety seven thousand dollars USD to disseminate information about (HILS:US) via digital communications. We own zero shares of (HILS:US). [( Fierce | 401 W. Atlantic Ave, Ste R10 Unit #271, Delray Beach, FL 33444 [Unsubscribe {EMAIL}]( [Update Profile]( | [Constant Contact Data Notice]( Sent by jaks@fierceanalyst.net